Back to Agenda
Symposium – Frailty as a Baseline Stratification Parameter and Potential Therapeutic Target
Session Chair(s)
Florian von Raison, DrMed
Senior Global Program Head and Chairman Geriatric Medicine Working Party/ EFGCP, Novartis Pharma AG, Switzerland
Progress made in drug development for and with older people? This session will announce and discuss the brand new EMA Geriatric Working Party frailty definition selected for study baseline characteristics for clinical studies and propose how this will change the research landscape in geriatric studies in Europe and beyond.
Speaker(s)
Susan Morgan
Medical Assessor, MHRA, United Kingdom
The EMA Geriatric Medicines Strategy, Good Pharmacovigilance Practice (GVP) and What Leads Us to Single out Frailty
Susanna Del Signore
Director and Founder, Bluecompanion Ltd, United Kingdom
SPRINTT- IMI
Antonio Cherubini, MD
Professor, IRCCS-INRCA, Italy
The Frailty Guideline under Consultation: What Does It Mean in Terms of CT Population and Registries?
Cynthia A Bens
Senior Vice President, Public Policy, Personalized Medicine Coalition, United States
Addressing Areas of Need / Insufficient Research
Francesca Cerreta, PharmD, MPharm, MS
Principal Scientific Officer, European Medicines Agency, Netherlands
Roundtable discussion
Have an account?